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The Prognostic Value of Combinations of Genetic
Polymorphisms in the ITGB3, ITGA2, and CYP2C19*2
Genes in Predicting Cardiovascular Outcomes
After Coronary Bypass Grafting
Yuriy I. Grinshtein,1 Aleksandra A. Kosinova,1 Igor Y. Grinshtein,2
Tatyana N. Subbotina,3 and Andrey A. Savchenko4
Aim: To determine if there is an association between the single nucleotide polymorphisms (SNPs): rs2046934,
rs1126643, rs5918, rs6065, rs4244285; rs4986893 and the occurrence of cardiovascular events (CVE) in patients
following coronary artery bypass grafting (CABG) surgery.
Materials and Methods: The study included 130 CABG patients with stable angina grades II–IV. After CABG
69 of the patients were treated with acetylsalicylic acid (ASA) alone, and 61 received dual antiplatelet therapy
(ASA+clopidogrel). Platelet function was assessed by light transmission aggregometry with adenosinedipho-
sphate and arachidonic acid. The SNPs were identified by real-time polymerase chain reaction (PCR) with
electrophoresis detection. The mean follow-up period was equal to 10.9– 5.2 months. The primary end point
included the composite of all-cause mortality, myocardial infarction (MI), and ischemic stroke.
Results: During the follow-up period 12 CVE were registered: 3 deaths, 6 MI, 3 strokes. Patients with
composite mutant alleles of ITGB3+CYP2C19*2 or CYP2C19*2+ ITGA2, and with the mutant allele (*2) of
CYP2C19, met end points more often than patients with other gene combinations (wild-type homozygotes,
presence of one mutant allele of ITGB3 or ITGA2, the composite of mutant alleles of ITGB3+ITGA2 or
ITGB3+ITGA2+CYP2C19*2; hazard ratio = 4, 95% confidence interval: 2.19–7.29, p= 0.008).
Conclusion: Carriage of a combination of mutant alleles in multiple genes including ITGB3+CYP2C19*2 or
CYP2C19*2+ ITGA2 or CYP2C19*2 are possible predictors of CVE in patients after CABG.
Keywords: artery bypass surgery, cardiovascular events, genetic predictors
Introduction
Platelets play a critical role in atherothrombosis. Theplatelet phenotype has wide variability due to heritable
differences in its reactivity, quantity, cell size, and membrane
receptors’ functions (Geisler et al., 2013). The studies of
siblings, twins, and families with a history of coronary artery
disease (CAD) have documented that intraindividual re-
sponsiveness is highly reproducible over time, regardless of
the agonist tested or the method chosen for assessment of
aggregation activity. These findings provide strong evidence
of a high heritability level of platelet function that has
prompted numerous attempts to define the genetic basis for
platelet function variability ( Jones et al., 2009). Up to 30% of
platelet function variability could be explained by genetic
heritability (Quinn and Topol, 2001).
Von Willebrand factor receptors, adenosine diphosphate
(ADP) receptors, collagen and fibrinogen receptors are the
main platelet receptors to take part in cell activation and
thrombus formation (Zuern et al., 2010).
Genetic research has carefully considered the association
of the above-mentioned receptors’ gene polymorphisms with
acute coronary syndrome, other cardiovascular diseases, and
atherothrombogenic outcomes (Cavallari et al., 2007; Ma-
guire et al., 2008; Hoppmann et al., 2014; Moon et al., 2017).
However, there is less evidence concerning the association of
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platelet receptors’ single nucleotide polymorphisms (SNPs)
with ischemic outcomes after coronary artery bypass grafting
(CABG) (Muslimova et al., 2017; Sarikaya et al., 2017).
As we know, carrying of a genetic polymorphism could
manifest phenotypically or remain inapparent. In case of
atherothrombosis, various risk factors could trigger the ap-
pearance of a trait encoded by relevant polymorphism.
CABG could be one of the predisposing factors of vessel
thrombosis. On the one hand it is a surgery aimed to improve
the quality of life, on the other it is a huge stress for the body
and hemostasis system. On-pump surgery damages cells, and
active substances flow into the blood: platelet adhesion and
aggregation stimulators, intercellular stimulators, endothe-
lium and system inflammation mediators; younger and more
active cells, particularly platelets, merge the bloodstream
(Grinshtein et al., 2009). The background of all this processes
is atherosclerosis with system inflammation. It is also known
that the risk of antiplatelet drugs resistance (aspirin and
clopidogrel—drugs for secondary prevention of thrombotic
events) is enhanced after CABG (Grinshtein et al., 2016).
Therefore, genetic polymorphisms of cytochrome P450, of
the enzyme that convert the prodrug to the active metabolite
in the liver, could be considered in association with cardio-
vascular outcomes (Moon et al., 2017).
Thus, the aim of our research was to study the association
of SNPs: rs2046934 (H1/H2: 744T<C) on P2RY12 (encoding
platelet ADP receptor); rs1126643 (807C>T) on ITGA2
(encoding collagen receptor); rs5918 (176T>C) on ITGB3
(encoding fibrinogen receptor); rs6065 (Thr145Met) on
GP1BA (encoding platelet receptor for Von Willebrand
factor); rs4244285 (*2) (681G>A) and rs4986893 (*3)
(636G>A) on CYP2C19 (encoding cytochrome P450 activ-
ity) with cardiovascular events (CVE) in patients with CAD
after CABG.
Materials and Methods
The study was conducted in the Krasnoyarsk Federal
Center of Cardiovascular Surgery from September 2012 to
December 2015. The study comprised 130 Caucasian pa-
tients (mean age of 62 – 8.3 years old) with stable angina
pectoris, grade II–III according to the Canadian Cardiovas-
cular Society classification.
All patients underwent CABG, 113 patients (87%) un-
derwent on-pump CABG, and 17 patients (13%) underwent
off-pump CABG.
Inclusion criteria were as follows: stable angina pectoris
grades II–IV, coronary artery atherosclerosis, proved by
coronary angiography, and written informed consent.
Exclusion criteria were as follows: renal failure, hepatic
failure, peptic ulcer and/or 12 duodenal ulcer in the acute stage,
and acetylsalicylic acid (ASA) or clopidogrel intolerance.
The control group included 185 healthy Caucasian vol-
unteers (74 women, 111 men) of mean age around 44.2 – 9.8
years, who were blood donors in Krasnoyarsk area blood
center from January 2012 to December 2015.
The study protocol was approved by the Ethics Committee
of the Krasnoyarsk State Medical University and conducted
according to the Helsinki Declaration with application of
Good Clinical Practice guidelines with written consents ob-
tained from all participants. Throughout the hospitalization
all patients were receiving therapy according to the Russian
Cardiology Society guidelines. Patients stopped the anti-
platelet treatment at least 5 days before CABG. In the post-
surgical period, patients were prescribed 100 mg of enteric
form of ASA alone (69 patients), or 100 mg ASA+clopido-
grel 75 mg per day (61 patients) since the first day after
CABG.
Blood specimens from the patients for platelet aggrega-
tion assay were obtained using test tubes containing 3.8%
sodium citrate filled at the ratio 9:1. Samples were processed
within 2 h after blood collection. For genetic analysis, whole-
blood samples were obtained from participants and col-
lected in EDTA tubes, stored at -18C. Platelet aggregation
was measured using a light transmission aggregometer (Chrono-
Log 490) with aggregation inductors: ADP 5mM or arachi-
donic acid (AA) 1 mM before CABG and on 1st–3rd, 8th–10th
day after CABG.
The genetic analysis was conducted in the Hematological
Research Center of the Federal State-funded Institution of
Russian Ministry of Health.
Genomic DNA from whole-blood samples was extracted
by standard methods using the reagent ‘‘DNA-EXPRESS-
blood’’ (Litekh). Genetic polymorphisms were detected by
polymerase chain reaction with the use of primers and re-
agents for amplification ‘‘SNP-express’’ and ‘‘SNP-express-
RT’’ (Litekh) for electrophoretic detection of amplification
products (by thermocycler Tercik; DNA-Technology) and
detection of amplification products in real time (by thermo-
cycler IQ-5; Bio-Rad) (Lytech.ru, 2011). In the obtained
DNA samples, the following polymorphisms were identified:
 H1/H2 haplotypes of the ADP platelet receptor gene
P2Y12, determined by assessing i-744T>C (rs2046934;
catalog No. for set: 01180);
 collagen receptor gene ITGA2 (807C>T, rs1126643;
catalog No. for set: S01155);
 fibrinogen receptor gene ITGB3 (176 T>C, rs5918;
catalog No. for set: S01106);
 and von Willebrand factor receptor gene GP1BA
(Thr145Met, rs6065) (catalog No. for set: 01179).
We equally studied the SNPs of cytochrome P450 gene
CYP2C19*2 (681G>A, rs4244285; catalog No. for set:
S01323) and CYP2C19*3 (636G>A, rs4986893; catalog No.
for set: S01324).
The mean follow-up period lasted 10.9 – 5.2 months.
Compliance was estimated by telephone contact. Only pa-
tients with high compliance were enrolled in the study. The
primary clinical end point was the cumulative incidence of
acute myocardial infarction (AMI), cerebral stroke, and all
causes death.
Statistical analysis
Data are presented as the mean – standard deviation for
continuous variables and as frequencies for categorical var-
iables. Continuous variables were compared between groups
using the Mann–Whitney-test (n< 30).
Allele frequency comparisons were predicted using the
Chi-square test. If a sample size fell short of five cases, the
Fisher’s exact test was used. The relative risks of the disease
for a particular allele or genotype were estimated by odds
ratios (ORs) (Bland and Althman, 2000). The OR was cal-
culated using the following formula: OR= (a$d)/(b$c), where
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allele (genotype) frequency in the patient sample, b—allele
(genotype) frequency in the hold-out sample, c—a total of
other allele (genotypes) frequencies in the patient sample, d—a
total of the other allele (genotypes) frequencies in the hold-out
sample. The OR is presented with 95% confidence interval (CI)
(Fleiss, 1989; Lakin, 1990). In the case of impossible estima-
tion of OR, the hazard ratio (HR) was used. All statistical
analysis was performed using SPSS version 20.0. Differences
were regarded as statistically significant if the null hypothesis
was rejected with probability >95% ( p < 0.05).
Results and Discussion
The results of DNA samples genotyping of volunteers and
patients with CAD are shown in the Table 1. While comparing
the frequency of genotypes rs5918, rs6065, rs2046934,
rs4244285, and rs4986893 in the group of patients with CAD
and the control group, there was no significant difference
declared. We should emphasize as well that no mutant allele A
of the polymorphism rs4986893 of cytochrome P450 gene—
CYP2C19*3 was found in neither the group of patients nor the
control group. That is the reason we excluded it from further
comparative analysis.
It is interesting to note that according to the literature, the
frequency of CYP2C19 genotypes (carrying allele variants of
CYP2C19*2 and CYP2C19*3—for slow metabolizers) in the
Russian population amounts to 11.4%, compared to Euro-
pean ethnic groups (Gaikovitch et al., 2003), but CYP2C19
genotypes, connected with slow metabolism, could be up to
27% in patients with chronic heart disease (CHD) (Komarov
Table 1. Genotypes Frequencies for Six Single Nucleotide Polymorphisms
in the Research Population and Control Group
Gene, SNP
Genotype,
allele
Frequencies in the research group
(patients with CHD), n = 130, n (%)
Frequencies in the
control group,
n = 185, n (%) p
ITGB3, 176 T>C, rs5918 TT n = 91 58 (63.5) n= 174 115 (66.1) 0.81
TC 31 (33.8) 54 (31.0)
CC 2 (2.7) 5 (2.9)
TT 58 (63.5) 115 (66.1) 0.57
TC+CC 33 (35) 59 (33.9)
T-allele 147 (80.8) 284 (83) 0.52
C-allele 35 (19.2) 58 (17)
GP1BA, Thr145Met, rs6065 CC n= 114 80 (70.1) n= 174 133 (76.4) 0.18
CT 30 (26.3) 38 (21.8)
TT 4 (3.5) 3 (1.7)
CC 80 (70.1) 133 (76.4) 0.24
CT+TT 34 (29.9) 41 (23.6)
C-allele 190 (83.3) 304 (87.4) 0.18
T-allele 38 (16.7) 44 (12.6)
ITGA2, 807 C>T, rs1126643 CC n = 94 44 (46.8) n= 171 56 (32.7) 0.025
CT 42 (44.7) 91 (53.2)
TT 8 (8.5) 24 (14.1)
CC 44 (46.8) 56 (32.7) 0.02
CT+TT 50 (53.2) 115 (67.3)
C-allele 130 (69.1) 203 (59.4) 0.03
T-allele 58 (30.9) 139 (40.6)
P2RY12, 744T>C, rs2046934 H1H1 n= 100 83 (83) n= 180 128 (71.1) 0.77
H1H2 19 (19) 43 (23.9)
H2H2 8 (8) 9 (5.0)
H1H1 83 (83) 128 (71.1) 0.42
H1H2+H2H2 27 (27) 52 (28.9)
T-allele 185 (84.1) 299 (83.1) 0.74
C-allele 35 (15.9) 61 (16.9)
CYP2C19*2, 681G>A, rs4244285 *1/*1 n = 84 69 (82.1) n = 30 23 (76.7) 0.42
*1/*2 14 (16.7) 6 (20.0)
*2/*2 1 (1.2) 1 (3.3)
*1/*1 69 (82.1) 23 (76.7) 0.51
*1/*2+*2/*2 15 (17.9) 7 (23.3)
*1allele 152 (90.5) 52 (86.7) 0.41
*2allele 16 (9.5) 8 (13.3)
CYP2C19*3, 636G>A, rs4986893 *1/*1 n = 83 83 (100) n = 30 30 (100) 1
*1/*3 0 0
*3/*3 0 0
H1—haplotype 139C, 744T, no, 52G; H2—haplotype 139T, 744C, ins801A, 52T; CYP2C19*2: variant *1/*1—genotype GG, *1/*2—
genotype GA, *2/*2—genotype AA; CYP2C19*3: *1*1—genotype GG, *1/*3—genotype GA, *3/*3—genotype AA.
CHD, chronic heart disease; SNP, single nucleotide polymorphism.
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et al., 2011). In our case, CYP2C19 genotypes connected
with slow metabolism demonstrated the frequency of 17.9%,
which is more often than in total population but less common
than in patients with CHD in other regions.
The frequency of mutant allele T of ITGA2 gene rs1126643
was significantly higher in the control group in comparison with
patients with CAD. Genotype CC was revealed in 46.8% of
patients, heterozygous CT genotype in 44.7%, and genotype TT
in 8.5% of them. In the control group, genotype CC was detected
in 32.7% of volunteers, heterozygous CT genotype in 53.2%,
and genotype TT in 14.1% (p= 0.025). Gene ITGA2 encodes
the amino acid sequence of integrin alfa2subunits (collagen re-
ceptors). Here, the allele 807C is associated with low density of
platelet membrane receptors and the allele 807T is associated
with high expression of the gene (Weiss et al., 1996).
According to the literature data, the allele variant fre-
quency of this polymorphism in the European population is
the following: CC—26.5%, CT—59.8%, and TT—13.7%
(Lewandowski et al., 2005), which compiles the frequency in
the control group in our study.
We did not detect any significant distinctions in platelet
aggregation with ADP (5 mM) and AA (1 mM) between pa-
tients with genotype CC and patients with genotypes CT plus
TT of polymorphism rs1126643 neither before CABG nor
1–3 and 8–10 days after CABG. Aggregation amplitude with
ADP before CABG and 1–3, 8–10 days after CABG in car-
riers of mutant T allele of polymorphism rs1126643 versus
carriers of dominant allele in homozygous genotype was the
following: 48.8%– 18.6%, 62.0% – 13.0%, 49.8%– 23.2%
versus 51.5%– 22.3%, 57.4%– 14.6%, 45.8%– 22.9, re-
spectively ( p = 0.497, 0.441, and 0.687). The estimation of
aggregation amplitude with AA before CABG, and on 1st–
3rd, 8th–10th days after CABG in carriers of mutant T allele
of polymorphism rs1126643 versus carriers of dominant al-
lele in homozygous genotype allowed us to reveal the fol-
lowing levels: 61.3%– 28.6%, 17.5% – 23.8%, 28.0 – 30.5
versus 71.3% – 21.8%, 16.9%– 22.7%, 29.9%– 33.5%, re-
spectively ( p = 0.416, 0.825, and 0.872). The polymorphism
rs1126643 was not associated with high platelet aggregation
after CABG.
The literature data about the association of the polymor-
phism rs1126643 with atherothrombosis are controversial. In
the meta-analysis of Wu et al. (2014) fifteen studies with
2242 cases and 2408 controls were included. This meta-
analysis has demonstrated an association between the C807T
polymorphism and the risk of ischemic stroke in the overall
Asians and the subgroup of hospital-based people population.
However, a statistical association was not found for Cauca-
sians and non-hospitalized individuals.
It is known that the glycoprotein (GP) Ia receptor or in-
tegrin a2b1 (platelet collagen receptor) refers to the integrin
family that takes part in the intercellular interaction. The
genotype 807TT is associated with high density of platelet
membrane receptors and high risk of retinal vessels throm-
bosis development, stroke, and myocardial infarction (MI)
(Dodson et al., 2003; Langsenlehner et al., 2006). However,
not all studies contain unambiguous data on this issue (Ye
et al., 2006; Gerger et al., 2009; Motovska et al., 2010).
Carriers of mutant allele from patients with CAD of
polymorphism rs5918 ITGB3 gene (the mutation that leads to
increased expression of fibrinogen receptors on the mem-
brane) may have higher levels of platelet aggregation with
AA on 1st–3rd day after CABG (1 mM). Aggregation am-
plitude with AA in mutant allele carriers was 27.5% versus
Table 2. The Aggregation Level in Patients with Coronary Artery Disease
with Different Genotype Variants of rs5918 in ITGB3 Gene
Index
Group of patients with
CAD (genotype TT), (n = 47)
Group of patients with CAD
(genotype TC+CC), (n = 24) p
APTT before CABG 28.7 – 3.2 27.9 – 3.2 0.308
Fibrinogen before CABG, g/L 3.1 – 0.69 3.1 – 0.7 0.746
PT before CABG 11.9 – 2.45 11.2 – 2.3 0.897
Platelet aggregation (amplitude) with 5 mM
ADP before CABG
52.0 – 23.5 56.8 – 21.0 0.561
Platelet aggregation (amplitude) with 1 mM
arachidonic acid before CABG
64.75– 26.5 60.96 – 29.9 0.761
Platelet aggregation (amplitude) with 5 mM
ADP at 1–3 days after CABG
59.1 – 15.8 66.4 – 15.0 0.074
Platelet aggregation (amplitude) with 1 mM
arachidonic acid at 1–3 days after CABG
12.7 – 16.2 27.5 – 31.1 0.016
Platelet aggregation (velocity) with 1 mM
arachidonic acid at 1–3 days after CABG
32.8 – 20.8 47.0 – 26.4 0.025
Platelet aggregation (lag-phase) with 1 mM
arachidonic acid at 1–3 days after CABG
23.9 – 42.6 30.2 – 61.3 0.616
Platelet aggregation (area) with 1 mM
arachidonic Acid at 1–3 days after CABG
55.6 – 74.9 97.9 – 103.6 0.040
Platelet aggregation (amplitude) with 5 mM
ADP at 8–10 days after CABG
38.4 – 23.9 44.7 – 22.0 0.228
Platelet aggregation (amplitude) with 1 mM
arachidonic acid at 8–10 days after CABG
32.9 – 31.8 24.3 – 26.7 0.160
Mann–Whitney test (n1 = 47, n2 = 24).
ADP, adenosine diphosphate; APTT, activated partial thromboplastin time; CABG, coronary artery bypass grafting; CAD, coronary
artery disease; PT, protrombin time.
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12.7% in carriers of homozygous dominant allele, aggrega-
tion velocity was 47% versus 32.8%, and area under the curve
97.9% versus 55.6%, respectively, ( p < 0.05). This fact em-
phasizes the necessity of the ASA administration even on the
first day after CABG. On the 8th–10th day of antiplatelet
treatment platelet aggregation characteristics did not differ
significantly (Table 2).
Numerous studies demonstrated the association between
allele C of the ITGB3 gene polymorphism (Leu33Pro,
rs5918) with increased platelet reactivity and aggregation
and/or fibrinogen binding capacity (Dropinski et al., 2007;
Lim et al., 2007). Other investigators did not find the influ-
ence of C allele on the platelet reactivity (Morawski et al.,
2005). In the study of Abderrazek et al. (2010), genotypes
frequency of platelet GPIII receptors gene were as follows:
TT—55.3%, CT—39.4%, and CC—5.3%.
Kucharska-Newton et al. (2011) in the study Athero-
sclerosis Risk in Communities (ARIC), with participation of
1202 patients, observed the mutant allele of polymorphism
rs5918 was associated with increased level of platelet acti-
vation (enhanced level of P-selecting expression) and ather-
oma cap thinning.
No differences in platelet reactivity among carriers of
other mentioned mutant alleles and wild types were observed.
In 34 patients, with full data concerning 6 studied poly-
morphisms, we have analyzed their association with CVE
after CABG. During the follow-up period 12 CVE were
registered: 3 strokes, 6 AMI, and 3 deaths.
We compared the group of patients that have met end
points (n= 12) and the group of patients without CVE during
the follow-up period by the presence of mutant alleles of
studied polymorphisms. It was indicated that the patients
with combinations of mutant alleles of ITGB3+CYP2C19*2
genes, CYP2C19*2 + ITGA2 genes, or mutant allele of
CYP2C19*2 gene met end points more often compared to
other gene combination (wild-type homozygote, presence of
one mutant allele of ITGB3 or ITGA2, the composite of
mutant alleles of ITGB3+ITGA2 or ITGB3+ITGA2+-
CYP2C19*2; p = 0.008, HR = 4, CI 2.19–7.29).
It should be mentioned that in listed variants of combina-
tion the one including mutant loss-of-function allele of
polymorphism rs4244285 of the cytochrome P450 gene, the
enzyme converting clopidogrel to its active metabolite, was
the most unfavorable. It is a polymorphism that is likely to
resist clopidogrel. Most of 12 patients who met end points (8
patients, 66.7%) after CABG received dual antiplatelet
therapy (due to the history of AMI and/or stenting less than a
year before CABG). Therefore, we may suggest that dual
antiplatelet therapy is less effective in adverse CVE pre-
vention in carriers of mutant allele combinations of ITGB3+
CYP2C19*2, CYP2C19*2 + ITGA2 genes, or mutant allele
of CYP2C19*2 gene.
According to the literature data, CYP2C19 allele frequency
differs within ethnic groups (Mirzaev et al., 2014). Sibbing
et al. (2009) demonstrated that 73% patients in German pop-
ulation were CYP2C19 wild-type homozygotes (*1/*1), 27%
had heterozygous type of *2 allele (*1/*2), and only 2% car-
ried mutant-type homozygotes CYP2C19*2 (*2/*2).
The features of clopidogrel pharmacodynamics and phar-
macokinetics depend on mutant allele carriage. It is well es-
tablished in RECLOSE trial (Varenhorst et al., 2009) where
772 patients were enrolled with different clinical variants of
CHD (ST elevation and non-ST elevation MI) undergoing
drug eluting stenting. Carriers of mutant allele CYP2C19*2
polymorphism had higher levels of ADP-induced platelet re-
activity than carriers of wild allele. Various studies have
demonstrated the association of mutant CYP2C19 allele with
weakened antiplatelet response to clopidogrel and high risk of
CVE (Collet et al., 2009; Frere et al., 2009).
A genetic substudy in TRITON-TIMI 38, with 1500 pa-
tients on clopidogrel treatment, showed significant increasing
risk of cardiovascular death, AMI, and stroke in carriers of at
least one mutant allele (27.1% of patients; OR 1.53, 95% CI
1.07–2.19, p = 0.01) (Mega et al., 2009).
The genetic substudy of 10,285 patients in PLATO trial
reported that loss-of-function CYP2C19(*2, *3–*8) alleles
associated with higher risk of CVE in a 30 days period (5.7%
vs. 3.8%, p= 0.028) in patients with AMI on clopidogrel
treatment. However, after 1 year period this distinction was
not significant (Wallentin et al., 2010).
In the analysis of Holmes et al. (2011) in 32 studies
(42,016 patients), the clinical relationship between genotype
and cardiovascular outcomes was not found, except stent
thrombosis. Substudies CURE and ACTIVE showed the
same results (Pare et al., 2010).
In our study, the mutant allele of cytochrome P450 gene
was not associated with CVE (Table 3). The carriage of
mutant alleles combination of cytochrome P450 gene, col-
lagen receptors gene, and fibrinogen receptors gene, but not
isolated carriage of mutant allele of cytochrome P450 gene
increased the risk of adverse CVE after CABG. This indicates
the necessity to investigate polymorphism combination in-
fluence on a factor but not the influence of a single poly-
morphism, especially if the encoded feature is involved in the
complex process.
It was logical to expect the probability of higher cardio-
vascular risk in patients with mutant allele combinations of
ITGB3+ITGA2+CYP2C19*2 genes, however, we did not
find this negative association because only one patient had
this combination.
This research has the limitation as the study group of pa-
tients after CABG was small.
Conclusions
The analysis of mutant allele association in the following
polymorphisms: rs2046934 of ADP-platelet receptor gene
Table 3. Association of Mutant Allele
of Single Nucleotide Polymorphisms
with Cardiovascular Outcomes After
Coronary Artery Bypass Grafting
Gene, polymorphism OR 95% CI p
ITGB3, 176 T>C, rs5918,
n= 80
0.284 0.032–2.486 0.225
GP1BA, Thr145Met, rs6065,
n= 101
0.563 0.112–2.820 0.484
ITGA2, 807 C>T, rs1126643,
n= 64
0.871 0.162–4.680 0.872
CYP2C19*2, 681G>A,
rs4244285, n = 73
1.543 0.279–8.532 0.619
P2RY12, rs2046934, n = 87 0.281 0.033–2.376 0.244
CI, confidence interval; OR, odds ratio.
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P2RY12; rs1126643 of collagen receptor gene ITGA2; rs5918
of fibrinogen receptor gene ITGB3; rs6065 of von Willebrand
factor receptor gene GP1BA; rs4244285 of cytochrome
P450 CYP2C19*2 gene; and rs4986893 cytochrome P450
CYP2C19*3 gene with primary end points has demonstrated
that patients who underwent CABG with mutant allele com-
binations of ITGB3+CYP2C19*2, CYP2C19*2+ ITGA2, or
CYP2C19*2 genes met primary end point more often com-
pared to carriers of other alleles combinations (wild-type
homozygote, presence of one mutant allele of ITGB3 or
ITGA2, or the composite of mutant alleles of ITGB3+ITGA2
or ITGB3+ITGA2+CYP2C19*2). Carriage of the combina-
tion of mutant alleles ITGB3+CYP2C19*2 or CYP2C19*2+
ITGA2 or CYP2C19*2 is a possible predictor of CVE in pa-
tients after CABG.
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